In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce how clinicians balance the benefits of treatment intensification with the potential for added toxicity in patients with metastatic ...
Dalia Kaakour, MD, MPH, highlights key findings from a retrospective review of cardiovascular system toxicities in patients initiating novel hormonal therapies for advanced prostate cancer. Kaakour is ...
NCCN now subdivides intermediate-risk NMIBC into three actionable strata, enabling more consistent selection of surveillance, intravesical therapy, and adjuvant intensification pathways. IBCG risk ...
The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results